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Abstract 
Objectives: To assess acceptability and feasibility of trial processes and the ReTrain 
intervention including an assessment of intervention fidelity. Design: A two-group, assessor-
blinded, randomised controlled trial with parallel mixed methods process and economic 
evaluations. Setting: Community settings across two sites in Devon. Participants: Eligible 
participants were: 18 years old or over, with a diagnosis of stroke and with self-reported 
mobility issues, no contraindications to physical activity, discharged from National Health 
Service (NHS) or any other formal rehabilitation programme at least 1 month prior, willing to 
be randomised to either control or ReTrain and attend the training venue, possessing 
cognitive capacity and communication ability sufficient to participate. Participants were 
individually randomised (1:1) via a computer generated randomisation sequence minimised 
for time since stroke and level of functional disability. Only outcome assessors independent 
of the research team were blinded to group allocation. Interventions: ReTrain comprised (1) 
an introductory one-to-one session; (2) ten, twice weekly group classes with up to two 
trainers and eight clients; (3) a closing one-to-one session, followed by three drop-in sessions 
over the subsequent three months. Participants received a bespoke home-based training 
programme. All participants received treatment as usual. The control group received an 
exercise after stroke advice booklet. Outcome measures: Candidate primary outcomes 
included functional mobility and physical activity. Results: Forty-five participants were 
randomised (ReTrain=23; Control=22); data were available from 40 participants at six months 
follow-up (ReTrain=21; Control=19) and 41 at nine months follow-up (ReTrain=21; 
Control=20). We demonstrated ability to recruit and retain participants. Participants were not 
burdened by the requirements of the study. We were able to calculate sample estimates for 
candidate primary outcomes and test procedures for process and health economic 
evaluations. Conclusions: All objectives were fulfilled and indicated that a definitive trial of 
ReTrain is feasible and acceptable. 
Registration: ClinicalTrials.gov: trial number NCT02429180. 
Funding: The Stroke Association TSA 2014-13 
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Strengths and limitations of this study 
 A community-based exercise intervention after stroke developed with service users 
 A pilot randomised trial developed following MRC guidelines on complex 
interventions 
 Mixed-method approach for answering feasibility and acceptability objectives 
 Objective physical activity capture via accelerometry but subjective self-report 
outcomes for functional mobility and psycho-social measurements 
 
 
 
4 
 
Introduction  
Five years after initial stroke, one in three individuals have residual physical impairment1, 
equating to over 300,000 individuals in the United Kingdom (UK) living with disability from 
stroke2. Provision of stroke rehabilitation is typically front loaded, with resources focussed on 
in-patient care and early supported discharge. Support tapers off after a few months3 with 
many individuals reporting unmet long-term needs4. 
The National Clinical Guideline for Stroke advise for secondary prevention that stroke 
survivors engage in 150 minutes of physical activity a week, in bouts of 10 minutes or more, 
starting light and developing across time to moderate levels of intensity5. However, many 
stroke survivors do not meet these recommendations6 7 due to combinations of personal (e.g., 
physical or psychological impairments) and environmental factors (e.g., lack of programmes 
and facilities). To address this problem, community-based programmes are promoted8-10. 
These tend to focus on cardiovascular fitness with less emphasis on functional improvements 
or on promoting on-going exercise self-management. National stroke guidelines5 identify the 
importance of interventions for functional improvement11 and self-management12 but 
evidence is lacking regarding these types of intervention13. 
Action for Rehabilitation following Neurological Injury (ARNI) is an approach aimed at 
improving function and facilitating self-management14 and has a detailed self-help book. The 
ARNI approach embodies a set of principles (e.g. instilling a commitment to regular exercise) 
and techniques tailored to individual need. The ARNI Institute trains registered exercise 
professionals to deliver key ARNI techniques. Clinical Commissioning Groups (CCGs), 
charitable, and local authorities have started to provide community-based ARNI training for 
stroke survivors, which has been positively received by participants, carers and 
practitioners15, however there is currently no randomised controlled trial (RCT) evidence for 
evaluating its impact on stroke outcomes or its cost-effectiveness.  
Background and objectives 
Using the Medical Research Council’s framework for the development and evaluation of 
complex interventions16 and considerable Patient and Public Involvement we have designed 
a testable programme called Rehabilitation Training (ReTrain)17-20. ReTrain is a community-
based, manualised group programme combining ARNI principles and key techniques with best 
practice guidelines for stroke9 17. The overall aim of our pilot RCT was to inform the design 
and delivery of a definitive RCT. Our objectives were to: 1) assess feasibility and acceptability 
of recruitment (target n=48), randomisation, allocation concealment and outcome 
assessment blinding; 2) determine  retention rates (target of less than 20% attrition); 3) check 
ReTrain’s acceptability and feasibility for participants, and refine the Trainer Manual; 4) test 
candidate outcome measures, assess their burden, levels of completion, and estimate 
outcome variance (to inform definitive trial sample size); 5) perform process evaluation 
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including intervention fidelity assessment; 6) calculate ReTrain costs and assess feasibility of 
collecting health and social service resource use. 
Methods 
A brief methods overview is provided in accordance with guidance for reporting pilot trials21; 
further details are available in the published protocol22. Ethics review was conducted by 
National Research Ethics Service Committee South West Cornwall & Plymouth (REC Ref: 
15/SW/04). 
Trial design  
ReTrain was a two-group, assessor-blinded, randomised controlled external pilot trial with 
parallel mixed methods process and economic evaluations. Eligible participants were 
individually randomised 1:1 to intervention (ReTrain) or control (exercise advice booklet23).  
Participants 
Inclusion criteria were: i) diagnosis of stroke; ii) any time since stroke but at least 1 month 
since discharge from NHS physical rehabilitation services; iii) able to walk independently 
indoors with or without mobility aids, but with self-reported difficulty with stairs, slopes or 
uneven surfaces; iv) willingness to be randomised and  attend the training venue; v) cognitive 
capacity and communication ability sufficient to participate.  
Exclusion criteria were: less than 18 years old, currently (or within one month of) receiving 
ARNI training or have contraindications to moderate to vigorous physical activity (adapted 
from American College of Sports Medicine guidelines24). Participants were recruited from two 
CCGs. Participants were identified by: (1) clinicians in NHS primary care, hospital and 
community stroke services; (2) contacts in the local Clinical Research Network and Clinical 
Research Facility; (3) promotion via local stroke support networks (e.g. Stroke Association); 
(4) word of mouth, study flyers and adverts.  
Intervention 
ReTrain aims to: (1) enhance function through task-related practice, teaching compensatory 
techniques, and providing targeted strength training (cardiovascular fitness gains also occur 
through these activities); (2) develop self-management skills for on-going rehabilitation; (3) 
deliver personalised training using negotiated goals and (4) instil a commitment to regular 
exercise for health improvement and longer-term maintenance. ReTrain facilitates safe and 
efficient practice of walking in varied terrains, kerbs, cambers and in crowds, turning and 
moving quickly, climbing steps and stairs without rails, getting to and from the floor without 
furniture or other aids, and moving without mobility aids or while carrying loads. Training is 
based on a manual and led by personal trainers on the UK Register of Exercise Professionals 
(level 3 or above) who are ARNI-trained and accredited and have had additional training in 
the delivery of ReTrain. There was a maximum ratio of one trainer to four stroke survivors. 
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ReTrain was delivered in a community setting (one gym, two church halls, one community 
centre) with twice weekly two hour sessions over three months, comprising: an introductory 
one-to-one session (home visit); ten, twice-weekly group classes with up to two trainers and 
eight clients (training venue); a closing one-to-one session (home visit); followed by three 
(one per month) drop-in sessions. Participants completed bespoke home-based training 
(homework) throughout. 
Control  
All participants received treatment as usual. This ranged from zero treatment to engagement 
with any health service(s). We requested that all trial participants did not participate in 
additional physical rehabilitation (either NHS or private) but we could not prevent them from 
doing so. We did not monitor control group participation in any treatments during the trial 
but did record health service use at the end of the trial for all participants. The control group 
also received an advice booklet about exercise after stroke23.  
Outcomes 
Feasibility, acceptability and process outcomes: numbers and details of those approached; 
recruitment and retention figures. Acceptability of randomisation, outcome measurement 
burden, and the intervention: completion of questionnaires and objective assessments; 
interviews with ten intervention and ten control group members, and the trainers. Safety: 
Adverse events25 identified via trainer and ReTrain participants (during the programme) and 
participant reports (all participants during 6 and 9-month assessments). Intervention fidelity: 
attendance registers, accelerometry, exercise ‘homework’ diaries, trainer completed session 
checklists and video analysis of (early, middle and late programme) training sessions.  
We tested a range of candidate primary and secondary outcome measures. Primary 
Outcomes: Rivermead Mobility Index26 27; Timed Up and Go Test28; modified Patient-Specific 
Functional Scale29; 7-day objective physical activity levels using wrist-worn accelerometry 
(GENEActiv, Activinsights, Kimbolton, Cambridge UK) and a physical activity diary. Secondary 
Outcomes: Stroke Self-efficacy Questionnaire30; Fatigue Assessment Scale31 32; exercise 
beliefs and exercise self-efficacy questionnaires33; SF1234; EQ-5D-5L35; Stroke Quality of Life 
(QoL) questionnaires36; Carer Burden Index37; and Health and Social Service use through a 
Service Receipt Inventory38.  
Physical outcome baseline assessments (completed by research team) and follow-up 
assessments (at 6 and 9-months, completed by blinded assessor) were conducted in the 
participant’s home. Researchers visited participants to fit the accelerometer, drop off 
questionnaires and diary one week prior to blind assessor visits. Assessors administered 
primary outcome physical measures and collected accelerometers, questionnaires and 
diaries. 
Sample size 
7 
 
We required 48 participants (24 per group) as (a) 30 complete data sets are recommended 
for pilot studies to estimate outcome variance39 and (b) we wanted to investigate variations 
in context by running the intervention three times (i.e. 3 x 8 patients). This number also 
allowed estimation of a predicted attrition rate of 20% with a precision of ± 5% with 95% 
certainty. 
Randomisation and blinding 
The random sequence was computer generated with minimisation for time since stroke (≤ 3 
months versus > 3 months) and level of functional disability (modified Rankin Scale (mRS)40 
score ≤ 2 versus > 2).  Allocation concealment was ensured by using a password protected 
validated web-based remote randomisation service supported by the Peninsula Clinical Trials 
Unit (PenCTU). The Trial Manager requested randomisation only after a cohort of participants 
had been consented. 
Participants, trainers providing the intervention, and researchers conducting the process and 
economic evaluations could not be blinded to allocation. However, outcomes were assessed 
by independent researchers (not based at research centre) who were blinded to group 
allocation. Participants were reminded not to reveal their allocation to assessors but any un-
blinding was recorded; after assessments assessors were asked to guess participant 
allocation. 
Data Analysis  
Analysis was primarily descriptive with participant flow summarised and estimates of 
screening, recruitment and attrition reported. Means and standard deviations for all 
outcomes are reported at baseline, 6 and 9-months follow-up for each group.  
Intervention fidelity was assessed using mixed methods: qualitative video analysis comparing 
the Trainer Manual standard versus observed technique (two researchers independently 
assessed videos) combined with interview data and summary scores from trainer completed 
session checklists. Qualitative data were manually analysed descriptively and with content 
analysis for trial processes; additional thematic analysis was used for interview data. One 
person (MN) led the qualitative analysis but this was then discussed (MN & SD), checked (RC) 
and agreed (MN, SD, LP, RC). 
We used a micro-costing approach to calculate costs associated with ReTrain: staff time 
(trainers, administrator, facilitators), venue hire, training equipment (annualised over time), 
course materials, consumables, travel costs (participants, trainers and facilitators). The costs 
of the intervention were estimated as a cost per programme and a cost per participant. The 
estimated costs of the intervention per participant were based on the number of participants 
enrolled on the programme. The base case scenario assumed the average number of 
participants per programme across all cohorts. Sensitivity analyses were conducted using the 
minimum and maximum number of participants enrolled for the programme and the quantity 
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of programme materials that were wasted. We analysed the relative benefits of calculating 
health related QoL using SF-6D (developed from the SF-12) over the QALY calculated (using 
EQ-5D 5L) from the baseline measures.  
Sample size estimates for a definitive trial were calculated for candidate primary outcomes 
using the standard deviation observed in this pilot population and published minimal clinical 
important difference (MCID) at 90% power and 5% alpha, and assuming 20% attrition. Where 
no published MCID could be sourced, we assumed a small to moderate effect size of 0.4 of a 
standard deviation41. The trial statistician undertook calculations using the ‘samspi’ command 
in STATA v14.2  
Results 
Recruitment took place from June 2015 to January 2016. The intervention ran in four cohorts, 
participant flows are shown for each (Figure 1) and for the trial overall (Figure 2). Initial 
recruitment was slow so to prevent late running of the trial we split the first cohort. Six-month 
follow-up outcome assessments took place January to July 2016 and 9-month follow-up April 
to October 2016.  
Objective 1: Assess the feasibility and acceptability of recruitment, randomisation, allocation 
concealment and processes for outcome assessment and blinding 
We screened 115 individuals to recruit 50 participants (Figure 1) in 8 months (2 months ahead 
of schedule). Of these, 45 (90%) were randomised (Figure 1 and 2). Five individuals withdrew 
prior to randomisation due to ill health or the time lag between agreeing to take part and a 
cohort being ready to randomise. Table 1 shows baseline characteristics of those randomised, 
indicating a balance of characteristics across trial arms.  
Table 1 Baseline participant demographics 
 ReTrain 
 (N= 23) 
Control 
(N=22) 
Gender, n   
Male (%) 16 (70%) 14 (67%) 
Age (years): mean  (SD) 70 (12) 71 (10) 
Age Category (N=45): n (%)   
<45 1 (4%) 0 (%) 
46-50 0 (0%) 1 (5%) 
51-60 3 (13%) 2 (9%) 
61-70 10 (43%) 6 (27%) 
71-80 5 (22 %) 8 (36%) 
81-90 2 (9%) 5 (23%) 
90+ 2 (9%) 0 (0%) 
Time Since Stroke (no. months):   
< 12 3 (13%) 3 (14%) 
12-24 4 (17%) 4 (18%) 
25-48 5 (22%) 5 (23%) 
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49-72  2 (9%) 5 (23%) 
73-96 4 (17%) 2 (9%) 
97+ 5 (22%) 3 (14%) 
Time Since Stroke Minimisation 
Categories (months):n, (%) 
  
<=3 months 1 (4%) 0 (0%) 
>3 months 22 (96%) 22 (100%) 
Type of Stroke, n (%)   
Haemorrhagic 3 (13%) 1 (5%) 
Ischaemic 15 (65%) 15 (68%) 
Both 0 (0%) 1 (5%) 
Missing 5 (22%) 5 (23%) 
Stroke Rehabilitation (weeks):    
             n,  
          Average no. weeks (SD) 
21, 
8 (9) 
21, 
14 (19) 
          Median no. weeks 6 12 
          Range 0-32 0-88 
          Unknown length rehab: n 2 1 
Functional Disability  
(Simplified Modified Rankin Scale 
score- sMRS): n (%) 
  
0 1 (4%) 0 (0%) 
1 2 (9%) 1 (5%) 
2 4 (17%) 9 (41%) 
3 16 (70%) 12(55%) 
sMRS minimisation categories: 
n(%) 
  
<=2 7 (30%) 10 (45%) 
>2 16 (70%) 12 (55%) 
Co-morbidities^, n (%)   
Hypertension 18 (78%) 18 (82%) 
Type 2 Diabetes Mellitus 4 (17%) 4 (18%) 
Depression 8 (35%) 5 (23%) 
Chronic Kidney Disease 2 (9%) 1 (4%) 
Asthma / COPD 4 (17%) 3 (14%) 
Other 5 (22%) 3 (14%) 
Medications^, n (%)   
Diuretics 3 (13%) 1 (5%) 
Anticoagulants 8 (35%) 10 (45%) 
Antiplatelet 15 (65%) 12 (55%) 
Antihypertensives 
        Calcium Channel Blockers 
        ACE inhibitors 
        Other 
 
6 (26%) 
13 (57%) 
9 (39%) 
 
14 (64%) 
8 (36%) 
7 (32%) 
Statins 18 (78%) 19 (86%) 
Anti-depressants 8 (35%) 5 (23%) 
Diabetes medication  4 (17%) 4 (18%) 
Chronic pain medication 12 (52%) 8 (36%) 
Other             5 (22%) 3 (14%) 
Employment Status, n (%)   
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Employed (and working) 2 (9%) 1 (5%) 
Retired 18 (78%) 15 (68%) 
Semi-retired 1 (4%) 0 (0%) 
Unemployed 2 (9%) 5 (27%) 
Pre-stroke Exercise History, n    
Exerciser (%) 10 (43%) 8 (36%) 
Mini Mental State Exam:   
n,  
Mean (SD) 
22*, 
27.5 (2.54) 
22, 
27.9 (3.01) 
Median 28 29 
Range 19– 30** 19-30** 
^ Participants may have more than one co-morbidity / medication. 
*1 participant with severe aphasia had difficulties completing the MMSE. The participant could 
understand and follow instructions and was considered cognitively able to participate in the 
trial.  
**Higher scores indicate better cognitive function. Participants range from no to moderate 
degree of cognitive impairment. 
 
Blinding of outcome assessors was considered successful as only 2/41 (5%) participants 
revealed their allocations after completion of outcome measures, both were intervention 
participants. Different assessors were used for subsequent assessments therefore risk of bias 
was minimised. 
Objective 2: Acquire retention rates and outcome variance  
Forty out of 45 (88%, 95% CI: 76% to 96%) completed 6-month and 9-month follow-ups. 
Despite fewer people being randomised than expected, high retention preserved the number 
of datasets needed to perform our sample size estimates (Table 2).  
Table 2 Sample estimates for potential candidate primary outcomes from ReTrain pilot RCT 
 
Primary Outcome Measure Sample Size 
Estimatesa 
Minimal 
Clinically 
Important 
Difference 
(MCID) 
Observed SD 
range 
Effect size 
(MCID/SD) 
Rivermead Mobility Index   36 – 44 3.0b 2.33 – 2.66 1.13 – 1.29 
Timed Up and Go  1,438 – 2,673 1.2 – 3.4c 15.69 – 21.39 0.06 – 0.22 
Modified Patient Specific 
Functional Scale  
16 – 200 1.0 – 3.0c 1.58 – 1.94 0.52 – 1.7 
Physical Activity 
(Accelerometer) 
350 - 1458 Not available Not applicable 0.2 – 0.45d 
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aFigures represent overall (two group) sample size estimates required for a definitive trial. 
Sample sizes estimated for 1:1 allocation at 90% power and 5% alpha and assuming 20% 
attrition. Calculations are conservative showing range from best case scenario (largest MCID 
and smallest SD) to worst case scenario (smallest MCID and largest SD) of SDs observed in this 
trial and published MCIDs where available.  
bMCID available from stroke research for the Rivermead Mobility Index 
(http://www.strokengine.ca/psycho/rmi_psycho/).  
cMCIDs identified from other disease groups used as proxies as no published stroke 
MCIDs42,43.  
dThere are no MCID data available for PA (accelerometry) in stroke (or any other cardio 
vascular disease) we therefore applied sample size calculations undertaken for a relevant 
ongoing HTA NIHR trial which estimated n= 562 (effect size 0.3) or n= 413 (effect size 0.35) 
(http://www.isrctn.com/ISRCTN15644451). 
 
Objective 3: Check ReTrain’s acceptability and feasibility for participants, and refine the 
Trainer manual  
Eleven themes from 20 qualitative interviews summarise participants’ views, Table 3 provides 
illustrative quotes. 
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Table 3 Participant quotes from qualitative interviews 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Study Information  
Participants considered information received as adequate. Five noted that information was 
limited, but most were unconcerned. Two added that too much information may have been 
detrimental to recruitment. Four others were satisfied with the information they received. 
b) Outcome Measure Burden 
Acceptability 
“It is ten weeks, you do it twice a week. Personally for the first say three or four weeks, I’d think well this is getting me nowhere, but 
then you think that you notice things, things are improving and at the end of ten weeks you want to go for twenty weeks (4:119-125) 
 
“I’d tell them [another stroke survivor] to go ahead and do it and to take it step by step and not to worry about it. Because you are 
treated with great respect, it was wonderful and they were. I’ll never be able to speak highly enough of them.” (25:388-390) 
 
Intervention approach 
“It opened my eyes to what can be done you know. How can I put it? It wasn’t as if I believed that I couldn’t do something it was 
being pointed in the right direction…heh I can do it…Great you’ve done it, you did it and you do it again. Yeah it was great” (4:358-
361). “It wasn’t easy at first, but I used to manage it” (5:246) 
 
“It was the way they addressed how you do your exercises. What it is doing to you and all the rest of it. Now to me that was 
absolutely important, because it made sense of why you are doing all this pumping up and down, and if you can’t do that, do this.” 
(22:252-255) 
 
“It was you felt as if you were a human being with them. You know and you were treated with respect…and although you couldn’t do 
things and you felt a bit of an idiot, they never let you feel like that” (25:567-572).  
 
“It’s a bit like playing scales…it’s not creative but as I gradually realise it, it could potentially be creative…doing something that I had 
been doing without thinking before and now couldn’t. …Now and again I walk without my stick without realising it, that’s creative I 
think.” (6:354-392) 
 
Impact of programme - psychologically 
“I suppose it is attitude of mind as much as anything. I mean I felt I’d gone through that stage of training and that I was going to get 
better. It built my spirit up…I felt as if it, well it was worth the three months you know and at the end of the day I hope I’m going to 
get back to something like normal”  (16:358-365) 
 
“It really helped me mentally, you know I thought right I can do this because before I was going into my shell, thinking I can’t do this 
and I can’t do that. Oh I am not going out. Then I went on that [ReTrain] and it gave me an element of confidence.” (43:562-565).  
 
Impact of programme – physically 
“you started to notice they are actually starting to fall into place. I don’t remember doing that last time. But I am doing it now great 
get on with it I am doing it faster now” (4:189-190) 
“I know if I went down which I did one day in the hall in the early stages of coming back home and I did manage to get up and walk 
upstairs…but I wouldn’t have been able to do that had I not had that [training]” (16:475-477) 
 
Homework adherence 
“trainers were always on about doings exercises at home…I could never pin him down to how long that should be for though” (6; line 
624). 
 
Programme technique adherence 
“I think that was the big thing you saw the benefits after the second, well the first or second session we had. ‘Oh we can do 
that!’…even if you were chastised, ‘come on get down, you have got to get up; you can do it!’ you know ‘try this’. There was a little 
trick which was another little thing of getting up from the ground which was, didn’t need any strength whatsoever and that was one 
of the big major things, especially for this other guy…doing it in a simple way of you know just sliding around and getting up using 
your own motio  of getting up…that m mentum is fantastic, lots of little things like that and you could see it worked.” (22:479-499). 
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Participants found the assessment process acceptable. Fifteen indicated no burden. Three 
participants indicated that they needed help from their carers to complete questionnaires, 
particularly recalling and reporting health resource use, placing a time burden on their carer. 
 
c) Venue 
Half of the ReTrain participants were very positive about the training venues. Important 
features were: space, provision of fluids (water, tea), easy availability of parking. For some 
the travelling distance was a concern; two noted their venue (a gym) was very noisy, 
insufficiently heated and the session time was too early. Some noted the small amount of 
equipment as an advantage (it aided transfer of exercises to their home) whereas others felt 
the equipment was not sufficiently specialist.  
d) Adherence to ReTrain (see also Objective 5) 
All ten ReTrain interviewees reported training in the five core (ARNI) techniques. Homework 
was discussed by all but lacked specificity, only two had clear homework examples that were 
effectively incorporated into their training. Although goal setting was a core element, only 
four specifically identified how their goals were linked into their overall programme. Three 
participants reported not attending drop-in sessions due to lack of information. Of three who 
attended two suggested the drop-ins repeated previous sessions.  
e) Group dynamics  
Group working was positively regarded and seen as integral to programme effectiveness. 
There were exceptions, one participant did not find ‘performing’ in public a positive 
experience. Likewise some suggested that groups reduced training intensity relative to one-
to-one training.  
f) Co-morbidities 
Participants identified several co-morbidities e.g.: knee replacements, cancer, angina, 
diabetes, amputation and depression. These had potential to impact on both the training and 
research participation but for most any concerns were accommodated by trainers. However, 
in one case some uncomfortable discussions occurred before an appropriate balance of 
perceived capability and training challenges was reached. Three participants with visual 
deficits, dyslexia and dysgraphia mentioned difficulties completing the research documents.  
g) Carer Health 
Two ReTrain participants commented on how commitment to the programme impacted on 
their partner’s health: one stopped attending sessions because the time away resulted in 
excessive strain on his wife; another expressed similar concern but did not stop attending.  
h) Trainer Manual 
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We refined the Trainer Manual throughout the study. Issues raised during interviews guided 
revisions including greater emphasis and clarification about use of goal setting, drop-ins, 
homework diaries, and managing participants with co-morbidities. 
Objective 4: Assess outcome completion and burden  
We collected baseline (n=41), 6-month (n=40) and 9-month (n=41) follow-up data on the 
majority of participants (Figure 2). Accelerometry wear time (24 hours for 7 days) was high, 
most having 6 or more valid days (≥ 16hrs per day, including ≥ 1 weekend day). Only two 
participants at baseline, one at 6-months and three at 9-months did not achieve 4 valid days 
of wear time. There was very little missing data. For three primary outcome measures there 
was only one participant with missing data at any given assessment time-point. For secondary 
outcomes there was either no missing data or only one to two participants with missing data 
at each time-point, apart from the exercise diary (between two and four participants with 
missing data at each time-point) and the Service Receipt Inventory (between three and seven 
participants with missing data). There were eight participants without accelerometer data at 
9-month assessment owing to hardware (device) and software (data extraction method) 
malfunctions.  
Objective 5: Perform process evaluation with an assessment of intervention fidelity 
We implemented a comprehensive video recording schedule (over 200 recordings) to capture 
participant and trainer adherence to key ARNI techniques. Both trainers and participants 
demonstrated high adherence. Modifications to techniques (to accommodate participant co-
morbidities) were captured and informed Trainer Manual development.  
We combined metrics from attendance registers and homework records to generate a 
‘dose’/adherence score, categorising individuals into low (< 50%), medium (50% - 75%) and 
high (>75%) adherence categories.  Of 23 ReTrain participants two did not receive the 
intervention (one returned to work; one withdrew from study), five had low adherence, five 
medium adherence, and eleven high adherence. These latter 16 (70%) were considered to 
have received sufficient ‘dose’ of ReTrain. 
Trainers varied in their completion of session checklists: pre-exercise and end-of-session 
components were less consistently reported compared to ARNI techniques but overall there 
was good adherence to programme delivery.  
Objective 6: Calculate the cost of intervention delivery and feasibility of collecting health and 
social service resource use. 
ReTrain costs were generated for each cohort, accounting for different programme sizes (four 
or eight participants) and venues. Costs per participant ranged from £615 to £972. The total 
per participant cost for ReTrain (assuming 24 participants) was £777. We conducted medical 
notes review on 35/41 participants and compared this ‘gold standard’ with self-reported 
health resource use. Participants reported using fewer resources compared to case notes 
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review. Data from medical notes informed the cost-utility and effectiveness frameworks for 
use in a definitive trial.  
Descriptive analysis of participant outcomes 
Primary and secondary outcome data are summarised in Table 4a and 4b respectively. 
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Table 4a: Number, means and standard deviations as a function of trial arm and measurement time point for candidate primary outcome measures in 
the ReTrain pilot trial 
Note: ^ post randomisation; *Average minutes of physical activity per day; aPrecision to 10 ms; bMeasurement recorded 100 times a second 
(accelerometer set to a sampling frequency of 100 Hz).
 Data collection time point 
 Baseline 6 month^ 9 month^ 
Measures: n, Mean (SD) 
 
ReTrain 
(N=23) 
Control 
(N=22) 
ReTrain 
(N=21) 
Control 
(N=20) 
ReTrain 
(N=21) 
Control 
(N=20) 
Rivermead Mobility Index 23, 
11.41 (3.05) 
22, 
11.68 (2.23) 
21, 
12.14 (2.73) 
19, 
12.47 (1.87) 
21, 
12.24 (3.27) 
20, 
12.65 (1.81) 
Modified Patient Specific Functional 
Scale 
22, 
2.95 (1.85) 
22, 
2.55 (1.23) 
21, 
3.47 (2.12) 
19, 
3.56 (1.69) 
21, 
3.25 (2.03) 
20, 
3.74 (1.86) 
Timed Up and Go (secs) a 23, 
27.57 (27.57) 
21, 
21.24 (11.18) 
21, 
20.76 (19.64) 
19, 
16.37 (9.69) 
21, 
20.76 (19.25) 
20, 
15.95 (12.00) 
Physical Activity: Diary* 
 
21, 
6.67 (19.20) 
20, 
10.69 (17.39) 
21, 
17.39 (24.28) 
19, 
25.60 (34.98) 
19, 
13.92 (22.25) 
20, 
35.11 (49.70) 
Physical Activity (Accelerometer): 
Total PA minutes*b 
21, 
145.10 (118.27) 
20, 
165.56 (139.09) 
19, 
134.88 (129.77) 
18, 
178.15 (155.07) 
16, 
152.08 (118.52) 
17, 
197.42 (144.31) 
Physical Activity (Accelerometer):  
Light PA minutes* b 
21, 
92.78 (93.15) 
20, 
110.18 (115.65) 
19, 
95.67 (105.50) 
18, 
121.80 (122.46) 
16, 
99.33 (99.54) 
17, 
134.54 (126.36) 
Physical Activity (Accelerometer):  
MVPA PA minutes* b   
21, 
52.32 (68.94) 
20, 
55.38 (39.66) 
19, 
39.21 (39.33) 
18, 
56.35 (51.26) 
16, 
52.75 (60.03) 
17, 
62.88 (41.73) 
Physical Activity (Accelerometer):  
Moderate PA minutes* b 
21, 
50.53 (66.77) 
20, 
53.38 (37.04) 
19 
37.73 (37.40) 
18, 
53.07 (43.99) 
16, 
51.11 (58.54) 
17, 
60.93 (40.84) 
Physical Activity (Accelerometer):  
Vigorous PA minutes* b 
21, 
1.79 (3.85) 
20, 
2.00 (3.96) 
19, 
1.48 (2.39) 
18, 
3.28 (8.14) 
16, 
1.64 (2.38) 
17, 
1.94 (2.33) 
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Table 4b: Number, means and standard deviations as a function of trial arm and measurement time point for candidate secondary 
outcome measures in the ReTrain pilot trial 
Note: ^ post randomisation; grey cells indicate measurement not taken at this time point
 Data collection time point 
 Baseline 6 month^ 9 month^ 
Measures: n, Mean (SD) 
 
ReTrain 
(N=23) 
Control 
(N=22) 
ReTrain 
(N=21) 
Control 
(N=20) 
ReTrain 
(N=21) 
Control 
(N=20) 
Fatigue Assessment Scale 23, 
27.17 (7.14) 
22, 
25.49 (7.44) 
21, 
24.05 (6.26) 
19, 
24.05 (8.86) 
20, 
27.45 (5.95) 
20, 
25.83 (9.14) 
Stroke Self-efficacy Questionnaire 22, 
72.41 (22.00) 
22, 
73.46 (17.87) 
  20, 
73.73 (19.63) 
20, 
74.40 (16.94) 
Outcome expectations for exercise 
Scale (Exercise Beliefs)  
23, 
3.66 (0.70) 
22, 
3.78 (0.52) 
  19, 
4.03 (0.59) 
19, 
3.73 (0.52) 
Short self-efficacy for Exercise Scale 
(Exercise self-efficacy) 
23, 
3.26 (0.92) 
22, 
3.32 (0.89) 
  19, 
3.32 (0.89) 
18, 
3.22 (1.06) 
Stroke Quality of Life  Scale(Total) 22, 
3.31 (0.68) 
22, 
3.45 (0.69) 
  20, 
3.38 (0.70) 
20, 
3.63 (0.82) 
EQ-5D-5L 22, 
0.51 (0.25) 
20, 
0.55 (0.24) 
  19, 
0.52 (0.24) 
20, 
0.62 (0.25) 
SF-12: Physical Component  21, 
33.12 (7.22) 
20, 
31.83 (6.69) 
  19, 
33.74 (6.44) 
19, 
33.25 (6.91) 
SF-12: Mental Component  21, 
50.10 (7.11) 
20, 
50.68 (7.98) 
  19, 
50.47 (6.51) 
19, 
48.05 (8.45) 
Modified Caregiver Strain Index 
(Carer Burden) 
 
8, 
11.39 (8.03) 
10, 
7.40 (7.83) 
  9, 
9.89 (7.22) 
6, 
9.50 (8.92) 
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Table 4a and 4b report mean scores across, respectively, candidate primary and secondary 
outcome measures at each time point of the pilot trial.  The trial was not powered to detect 
differences in outcome between trial arms or over time and so we do not interpret the 
patterns of means. However, the results clearly demonstrate that we were able to collect 
the necessary data and retained acceptable completion rates on all measures across all time 
points of the study. Attrition was lower than the 20% expected. For each outcome measure 
(except carer burden as not everyone had a carer) we achieved in excess of the 30 cases (i.e. 
15 completed measurements per arm) recommended for pilot studies to estimate outcome 
variance. 
Safety  
During assessment periods there was one serious but unrelated event in the intervention 
group (none in the control group) and slightly fewer overall adverse events in the intervention 
group (Table 5a).  
Table 5a: Adverse Events (AE) and Serious Adverse Events (SAE) reported during 6 
and 9-month outcome assessment periods for both ReTrain and Control group  
 
 
 
 
 
 
 
 
 
a: Muscle soreness (n=26); fatigue (n=58); falls (n=12); trips (n=10); other (n=19; 
including but not limited to: low mood, itchiness, colds, issues with eyesight, cystitis). 
b: Ambulance conveyance to A&E due to reaction to antibiotics being taken for chest 
infection. 
c: Muscle soreness (n=39); fatigue (n=50); falls (n=19); trips (n=12); other (n=30; 
including but not limited to: low mood, depression, dizzy spells, sore toes, poor 
memory, colds, poor sleep, loss of sense of smell, issues with eyesight). 
  
 Event 
Type 
Total 
Events 
Attribution N People 
Reporting 
Event 
ReTrain 
(N=21) 
  Related Probably 
Related 
Possible 
Related 
Unrelate
d 
 
 
AE  125a 6 5 73 41 19 
 
SAE 1b 0 0 0 1 1 
Control 
(N=20) 
Event 
Type 
Total 
Events 
Related Probably 
Related 
Possible 
Related 
Unrelate
d 
N People 
Reporting 
Event  
AE 150c 0 0 0 150 19 
 
SAE 0 0 0 0 0 0 
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Table 5b: Adverse Events (AE) and Serious Adverse Events (SAE) reported during 
ReTrain programme  
 
 
 
 
 
 
a: Muscle soreness (n=0); fatigue (n=2); falls (n=10); trips (n=1); other (n=9; including 
but not limited to: fainting; twisted or swollen ankle, suspected TIA (non-confirmed)). 
b: Urine retention (n=3); black-out/fainted (n=1); renal & heart failure (n=1); TIA (n=1).  
For ReTrain only (Table 5b) there were six serious adverse events during the intervention 
period: four were unrelated, one possibly related (fainted) and one probably related (TIA) to 
the intervention. Of the 22 adverse events reported, three of them occurred at the venue (1 
x fall; 1 x trip; 1 x ankle strain). 
Discussion 
The ReTrain pilot trial met all its pre-stated feasibility objectives: the intervention, trial design 
and research processes were acceptable to participants as well as feasible and safe to deliver; 
we demonstrated feasibility of recruitment (recruiting above our target of 48), and retention 
(less than 20% attrition). At the point of randomisation we were slightly under target (45/48). 
However due to high retention we preserved the number of datasets required (30) to 
calculate sample size estimates. Furthermore, participants were not unduly burdened by 
study requirements and there were high completion rates for most outcome measures. We 
also successfully rehearsed procedures for process and health economic evaluations as well 
as trial governance processes (trial management and independent trial steering meetings) 
and maintained our strong Patient and Public Involvement. Participant interviews, outcome 
measurement results and fidelity assessments highlighted refinements that we have already, 
or can, put in place for a future definitive RCT of ReTrain. For example, we have some new 
insights into how to enhance delivery by trainers and engagement by participants (e.g. by 
placing more focus on individually tailored goal setting; stressing goal and homework reviews; 
better explanation and promotion of the drop-in sessions). These are all relatively small 
amendments that are likely to enhance the impact of the training programme. Our trial 
compares favourably with another feasibility RCT assessing the delivery of the Bridges stroke 
self-management programme44 which had relatively low recruitment, questions regarding 
programme delivery in addition to usual rehabilitation, and recommendations for further 
 Event 
Type 
Total 
Events 
Attribution N People 
Reporting 
Event 
ReTrain 
(N=21) 
  
Related Probably 
Related 
Possible 
Related 
Unrelate
d 
 
 AE  2a 7 0 12 3 11 
 SAE 6b 0 1 1 4 5 
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assessment of intervention fidelity. Some of their findings were similar to ReTrain: 
participants were broadly positive about their programme; health professionals found it 
acceptable to use and researchers noted the lack of outcome measure sensitivity for 
detecting change44.     
Limitations and lessons for planning design of a future trial 
When planning this study we selected our candidate primary outcome measures on the basis 
that they were likely to measure improvements that could be attributed to our intervention; 
our pilot work was therefore to determine acceptability and feasibility (including their 
psychometric utility) of these measures. However we were not able to identify a clear 
candidate primary outcome for a definitive RCT from this pilot work. It is possible that an 
‘activities of daily living’ measure (as typically used in rehabilitation studies) may be more 
useful in a future definitive trial. Identifying robust outcome measures in rehabilitation trials 
is a common problem45 compounded by variability in stroke related disability and 
participants’ comorbidities. This pilot trial was not designed (statistically powered) to test for 
differences between treatment arms, so no inferential analyses were performed. Any 
perceived trend (or absence of a trend) should not be interpreted as an indication of an effect 
(or its absence) and outcomes should not be selected based upon any assumed trend. 
Acceptability outcomes coupled with a pragmatic and efficient (cost-effective) trial design 
better inform choice of outcome. From our sample the Timed Up and Go task would be 
unsuitable due to potentially large sample size requirements (~2000 participants) and the 
baseline high levels of mobility meant the Rivermead Mobility Index demonstrated a ceiling 
effect, so could only be used if we altered inclusion criteria. Physical activity was measured 
robustly via accelerometry and may be the best candidate. We had some software and 
hardware malfunctions but important lessons have been learned to mitigate these problems 
in future. Capture of frequency and intensity of activity would allow comparison with stroke 
guidelines. Although there is a cost implication, accelerometry provides a more objective 
measurement of daily activity and may also be an adequate proxy of functional mobility, 
however we will also investigate the benefits of using other PA measures such as 
questionnaires (instead of our diaries) or using multiple measures such as accelerometry and 
heart rate monitors whilst being aware of problems with compliance and participant 
burden46.  
Further limitations relate to the lack of validation of our adherence measure and the local 
demographics: our sample did not have a wide age range or ethnic diversity. Whilst we did 
demonstrate delivery in different locations in the South West our plans for a larger definitive 
trial would include a wider demographic from more centres across the UK.  
For a future trial we plan to implement more readable, higher quality written (and pictorial) 
information and questionnaires although the amount of information provided was 
appropriate. We will mitigate recruitment loss prior to randomisation by establishing 
expression of interest and eligibility to take part but delaying taking consent until we are 
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confident of sufficient numbers to create a cohort for randomisation; this has resource 
implications that will need to be built into future funding.  We will run ReTrain in community 
centres or halls as these were more acceptable and much cheaper than gyms; we will provide 
a more detailed ReTrain induction to ensure trainers understand and communicate all 
components of the programme. For the QALY comparisons recent policy changes mean the 
conversion from SF-12 to SF-6D has been phased out, and so less justification for using the 
SF-12 in a future study.  Instead we will consider using the Stroke Impact Scale (SIS) as this is 
a valid health-related QoL measure. This may also be a better candidate self-report primary 
outcome measure for a definitive trial as it has shown sensitivity in long-term stroke survivors 
who have mild to moderate stroke47. The SIS assesses multiple facets of physical and 
emotional issues and so would align with perceived physical and psychological benefits 
participants attribute to ReTrain. Our sample size estimates for candidate objective primary 
outcomes (Table 2) indicate we will need a moderately sized trial (n=562, effect size 0.3 or 
n=413, effect size 0.35) for PA assessed by accelerometry or a smaller trial (n=96) if we use 
the physical component domain of the SIS (based on 80% power, 5% alpha and assuming 20% 
attrition48). We have established appropriate process evaluation methods to capture multiple 
facets of intervention fidelity.  
Generalisability 
This pilot study was not designed to demonstrate generalisability however our participant 
population represent the sub-set of community-dwelling stroke survivors who have some 
independent mobility but remain with stroke-related disability that affects their QoL. Our 
participants also represent the growing proportion of people who have more than one long-
term condition. ReTrain techniques target the effects of stroke but can accommodate other 
conditions which trainers take into account when preparing the participant’s individually 
tailored programme. Some of the key ReTrain (ARNI based) techniques are designed for 
people with unilateral impairment, such as hemiparesis; however one of our participant’s 
main unilateral impairment was due to diabetes related lower limb amputation, illustrating 
how ReTrain can accommodate people with multiple co-morbidities.  
Conclusion 
Our pilot trial has demonstrated that ReTrain is feasible, acceptable, and safe. We met our 
recruitment and retention targets and demonstrated our ability to run our intervention in 
different locations. Participants were not unduly burdened by study requirements and most 
outcome measures had high levels of completion. We successfully tested procedures for 
process and health economic evaluations. Participant interviews, outcome measurement 
results and fidelity assessments highlighted some issues needing refinement prior to a future 
definitive RCT of ReTrain. Many of these have already been addressed and we intend to seek 
funding for a definitive trial.  
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Figure 1 – Recruitment and randomisation by cohort 
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Figure 2 – Participant flow through the trial 
 
 
 
